Real-world outcomes (RWO) of oral MET-inhibition in EGFR MET-amplified (MET-amp) NSCLC

Tagrisso (osimertinib) - AstraZeneca

gefitinib - Generic mfg.

erlotinib - Generic mfg.

vebreltinib (APL-101) - Apollomics

Tabrecta (capmatinib) - Novartis

Tepmetko (tepotinib) - EMD Serono

nazartinib (EGF816) - Novartis

Orpathys (savolitinib) - AstraZeneca, Hutchmed

https://cslide.ctimeetingtech.com/coasis_21526/attendee/confcal_1/presentation

Y.L. Teh 1; W.L. Tan 1; W.C. Tan 1; Y. Chuang 1; L.Y. Wang 1; G. Lai 1; A. Tan Chia-Ken 1; P.L.S. Saw 1; A. Seet 1; S.Y.N. Wong 1; R. Sim 1; A. Jain 1; J. Chan 2; Q.S. Ng 3; J. Chew 1; M. Ang 1; R. Kanesvaran 4; D.W. Lim 1; D.S.W. Tan 1

Feb 5, 2026